42 research outputs found

    Health week: an experience of working with the circle

    Get PDF
    Enfermera y profesora en el IES Castillo de Matrera de Villamartín en la provincia de Cádiz, desarrollo mi labor docente con alumnos y alumnas de los Ciclos Formativos: Técnico Superior de Laboratorio Diagnóstico Clínico y con Auxiliares de Enfermería (Ciclo de Grado Medio). La experiencia que presento a continuación, es la denominada “Semana Sanitaria”. Acción que se organiza como actividad complementaria desde hace varios años en el centro y que se dirige al alumnado de los ciclos formativos en los que imparto docencia, con la intención de que los alumnos/as se familiaricen con el mundo laboral que próximamente les espera. Esto lo llevamos a cabo contactando con diferentes centros, asociaciones y empresas del entorno y dándoles a conocer a profesionales en activo que les muestren de una manera directa la organización y consecución de sus profesiones. El motivo que hace que la actividad se repita cada año es la buena acogida y ventajas que aporta tanto a profesores, como a los profesionales que intervienen y principalmente al alumnos/as del centro. Este curso, como coordinadora de la actividad doy las gracias a todos ellos porque sin su colaboración no hubiera sido posible realizar la experiencia y compartir tantas vivencias

    Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection

    Get PDF
    Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components. Dendritic cells (DCs) play a key role in the defense against viral infections, for instance plasmacytoid DCs (pDCs), have the capacity to produce vast amounts of interferon-alpha (IFN-α). In COVID-19 there is a deficit in DC numbers and IFN-α production, which has been associated with disease severity. In this work, we described that in addition to the DC deficiency, several DC activation and homing markers were altered in acute COVID-19 patients, which were associated with multiple inflammatory markers. Remarkably, previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+ myeloid DCs and pDCs seven months after SARS-CoV-2 infection. Moreover, the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients, while no restoration of integrin β7 and indoleamine 2,3-dyoxigenase (IDO) levels were observed. These findings contribute to a better understanding of the immunological sequelae of COVID-19

    SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome

    Get PDF
    The aim was to assess the ability of nasopharyngeal SARS-CoV-2 viral load at first patient’s hospital evaluation to predict unfavorable outcomes. We conducted a prospective cohort study including 321 adult patients with confirmed COVID-19 through RT-PCR in nasopharyngeal swabs. Quantitative Synthetic SARS-CoV-2 RNA cycle threshold values were used to calculate the viral load in log10 copies/mL. Disease severity at the end of follow up was categorized into mild, moderate, and severe. Primary endpoint was a composite of intensive care unit (ICU) admission and/or death (n = 85, 26.4%). Univariable and multivariable logistic regression analyses were performed. Nasopharyngeal SARS-CoV-2 viral load over the second quartile (≥ 7.35 log10 copies/mL, p = 0.003) and second tertile (≥ 8.27 log10 copies/mL, p = 0.01) were associated to unfavorable outcome in the unadjusted logistic regression analysis. However, in the final multivariable analysis, viral load was not independently associated with an unfavorable outcome. Five predictors were independently associated with increased odds of ICU admission and/or death: age ≥ 70 years, SpO2, neutrophils > 7.5 × 103/µL, lactate dehydrogenase ≥ 300 U/L, and C-reactive protein ≥ 100 mg/L. In summary, nasopharyngeal SARS-CoV-2 viral load on admission is generally high in patients with COVID-19, regardless of illness severity, but it cannot be used as an independent predictor of unfavorable clinical outcome

    Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

    Get PDF
    Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER).Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population

    Role of age and comorbidities in mortality of patients with infective endocarditis

    Get PDF
    [Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

    Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy:Study protocol of a cluster randomized clinical trial (Multi-PAP project)

    Get PDF
    This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD12/0001/0012, RD16/0001/0005), and the European Regional Development Fund ("A way to build Europe").Background: Multimorbidity is associated with negative effects both on people's health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (≥3 chronic diseases) and polypharmacy (≥5 drugs prescribed in ≥3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799Publisher PDFPeer reviewe

    Genomic investigations of unexplained acute hepatitis in children

    Get PDF
    Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis in children have been reported worldwide, including 278 cases in the UK1. Here we report an investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator participants, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in the liver, blood, plasma or stool from 27 of 28 cases. We found low levels of adenovirus (HAdV) and human herpesvirus 6B (HHV-6B) in 23 of 31 and 16 of 23, respectively, of the cases tested. By contrast, AAV2 was infrequently detected and at low titre in the blood or the liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded the emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T cells and B lineage cells. Proteomic comparison of liver tissue from cases and healthy controls identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV-mediated and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and, in severe cases, HHV-6B may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children

    Absorción de grasas termoxidadas. II. Influencia del nivel de alteración y porcentaje de grasa en la dieta

    No full text
    [EN]: In this paper, the influence of dietary fat alteration and level upon digestibilities of total fat, unsaponifiable matter and non-altered fatty acids, is studied. 11 groups of Wistar rats were fed diets containing non-heated and thermoxidized olive oils. Analytical techniques previously studied were used for isolation and evaluation of non-absorbed lipids present in feces. The results obtained led to the following conclusions: - Digestibility of fat decreases with dietary fat alteration but it is independent of the dietary fat level. - The apparent absorption of non-altered fatty acids is affected by the dietary fat alteration. - Dietary fat alteration significantly contributes to increase excreted levels of unsaponifiable from endogenous sources.[ES]: En el presente trabajo se estudia la influencia de la alteración y porcentaje de grasa en la dieta sobre la digestibiiidad de la grasa total así como de las fracciones insaponificable y de ácidos grasos no alterados. La experiencia fue realizada utilizando 11 grupos de ratas Wistar alimentadas con aceites de oliva no calentado y termoxidado. Se aplica-ron técnicas analíticas estudiadas con anterioridad para la extracción y evaluación de los lípidos no absorbidos presentes en heces. Los resultados obtenidos permiten deducir las siguientes conclusio-nes: - La digestibiiidad de la grasa disminuye con el incremento de alte-ración, pero es independiente del nivel de grasa en la dieta. - La absorción aparente de ácidos grasos no alterados se encuentra afectada por la alteración de la grasa de la dieta. - La alteración de la grasa ingerida contribuye al aumento de las cantidades excretadas de insaponificable de origen endógeno.A la Junta de Andalucía y a la Comisión Interministerial de Ciencia y Tecnología (Proyecto AL! 88-0208), por la financiación aportada. A la Sra. Mercedes Giménez, por la ayuda prestada

    Absorption of thermoxidízed fats. I. Reproducibility and accuracy of the previous analytical techniques used for the evaluation of non-absorbed lipids

    No full text
    [ES]: Se estudia la exactitud y reproducibilidad de las técnicas analíticas utilizadas en la extracción y separación de lípidos no absorbidos presentes en las heces de ratas Wistar alimentadas con dietas conteniendo aceites termoxidados. Se ha encontrado una reproducibilidad muy elevada en la cuantificación de lípidos totales, ácidos grasos no polares y composición en ácidos grasos. Por otra parte, la comparación de los lípidos extraídos de las dietas con sus correspondientes aceites de partida, demuestra en primer lugar una total recuperación de la grasa en el proceso de extracción y en segundo ausencia de alteración significativa durante el mismo. Los lípidos no absorbidos se caracterizan por un elevado contenido en ácidos grasos polares y compuestos no saponificables.[EN]: Reproducibility of the techniques used for isolation and separation of non-absorbed lipids present in feces from rats fed with diets containing heated oils are defined. Highly reproducible results have been found for total lipids, nonpolar fatty acid compositions. Results obtaines from extracted diets demonstrate both the absence of significant alteration and the complete extraction of the fat when compared to those obtained directly from the oils. Non-absorbed lipids from diets containing thermoxidized oils are characterized by high proportions of unsaponifiable compounds and polar fatty acids.A la Junta de Andalucía y a la Comisión Interministerial de Ciencia y Tecnología, por la financiación aportada.Peer reviewe
    corecore